

## 47. Getting patients treated for latent TB infection (LTBI) as TB prevention

**THE 46<sup>TH</sup> UNION  
WORLD CONFERENCE  
ON LUNG HEALTH**

CAPE TOWN, SOUTH AFRICA  
2-6 DECEMBER 2015

Saturday, 05 December 2015, 15:30 - 17:00

Room MR 2.44-2.46

Type of session	Symposium
Track	Latent TB infection (LTBI)
Track2 (optional)	Patient-centred care
Description	WHO issued new guidelines for who should be tested and treated for latent TB infection (LTBI). Treatment of TB infection can function as TB prevention and strategies to maximize treatment completion for those most at risk of TB is important. This symposium will discuss the evidence for best use of diagnostic tests and treatment regimens. The session will cover: the new WHO guidelines for management of latent TB infection; considerations for predictive value of the TB tests, including interferon gamma release assay (IGRA); programme experience of short LTBI regimens; and an update on LTBI research.
Target audience	1. National TB programme managers, TB researchers, TB programme staff, healthcare workers, clinicians
Objectives	<ol style="list-style-type: none"> <li>1. To inform the target audience of the new WHO guidelines for management of latent TB infection</li> <li>2. To review the latest data on IGRA's for predicting progression to active TB</li> <li>3. To assist programs in implementing LTBI treatment by sharing experiences from low- and high-burden settings</li> <li>4. To discuss ongoing or planned studies that address research gaps in LTBI</li> </ol>
Keywords	Preventive therapy; clinical trials; guidelines
Coordinator(s)	Sarita Shah (USA), Christine Ho (USA)
Chair(s)	Christine Ho (USA), Hendrik Simon Schaaf (South Africa)
Presentations	<p><b>15:30 - 15:40</b> Addressing latent TB infection to achieve global TB elimination targets: new WHO guidelines for LTBI Haileyesus Getahun (Switzerland)</p> <p><b>15:45 - 15:55</b> Identifying those at highest risk for progression: role of next generation IGRAs in targeting treatment Mark Hatherill (South Africa)</p> <p><b>16:00 - 16:10</b> Implementing shorter LTBI treatment regimens in low-incidence settings: lessons learned from 3HP post-marketing surveillance Christine Ho (USA)</p> <p><b>16:15 - 16:25</b> Implementing LTBI treatment in high incidence settings: lessons learned Bui Duc Doung (Viet Nam)</p> <p><b>16:30 - 16:40</b> Update on clinical trials for LTBI: towards shorter regimens for HIV and non-HIV infected persons Gavin Churchyard (South Africa)</p> <p><b>16:45 - 17:00</b> Discussion</p>